The DOI matches its Crossref record.
Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide.
Open accessAbstract
Indoleamine 2,3-dioxygenase [indoleamine: oxygen 2,3-oxidoreductase (decyclizing)] activity in the supernatant fraction (30,000 X g, 30 min) of the mice lung homogenate increased approximately 30- to 50-fold after an intraperitoneal administration of bacterial lipopolysaccharide. In all other tissues tested, no significant increase in enzyme activity was observed. The effect appeared to be specific for the lipopolysaccharide fraction because glycogen and zymosan were almost ineffective under the same experimental conditions. In the lung, the enzyme activity increased almost linearly during the first 24 hr after a single injection of the lipopolysaccharide fraction (20 microgram per mouse). The enzyme activity started to decrease after 48 hr and reached a normal value after about 6 days. The increase in enzyme activity was completely abolished by cycloheximide or actinomycin D. Other enzymes in the lung such as beta-glucuronidase, acid phosphatase, and monoamine oxidase did not change significantly with this treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A guide to immunometabolism for immunologists
O'Neill, L. A. J., Kishton, R. J., & Rathmell, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.70 · Cited by 3,315
Sono, M., Roach, M. P., Coulter, E. D., & Dawson, J. H. (1996) · Chemical Reviews · doi:10.1021/cr9500500 · Cited by 2,441
Terness, P., Bauer, T. M., Röse, L., Dufter, C., Watzlik, A., Simon, H., & Opelz, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020052 · Cited by 937
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899
Tryptophan and the immune response
Moffett, J. R., & Namboodiri, M. A. (2003) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.2003.t01-1-01177.x · Cited by 760
Amino Assets: How Amino Acids Support Immunity
Kelly, B., & Pearce, E. L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.010 · Cited by 643
Melillo, G., Musso, T., Sica, A., Taylor, L. S., Cox, G. W., & Varesio, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1683 · Cited by 626
Favre, D., Mold, J., Hunt, P. W., Kanwar, B., Loke, P., Seu, L., Barbour, J. D., Lowe, M. M., Jayawardene, A., Aweeka, F., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000632 · Cited by 523
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
IDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 437
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase.
Takikawa, O., Yoshida, R., Kido, R., & Hayaishi, O. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35696-x · Cited by 377
Self-citationThomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 367
Zhen, X., Zhang, C., Xie, C., Miao, Q., Lim, K. L., & Pu, K. (2016) · ACS Nano · doi:10.1021/acsnano.6b02908 · Cited by 340
Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism
Takikawa, O. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.032 · Cited by 337
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Dioxygenase enzymes: catalytic mechanisms and chemical models
Bugg, T. D. H. (2003) · Tetrahedron · doi:10.1016/s0040-4020(03)00944-x · Cited by 329
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Samsel, A., & Seneff, S. (2013) · Entropy · doi:10.3390/e15041416 · Cited by 293
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.
Yoshida, R., Imanishi, J., Oku, T., Kishida, T., & Hayaishi, O. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.129 · Cited by 292
Self-citationEnzymology of NAD+ homeostasis in man
Magni, G., Amici, A., Emanuelli, M., Orsomando, G., Raffaelli, N., & Ruggieri, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3161-1 · Cited by 288
Reconstructing eukaryotic NAD metabolism
Rongvaux, A., Andris, F., Van Gool, F., & Leo, O. (2003) · BioEssays · doi:10.1002/bies.10297 · Cited by 280
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2009) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259
Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches
Dantzer, R. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_6 · Cited by 248
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141
“Within the CNS, IDO is the predominant enzyme, expressed by most human brain cells (Guillemin et al. 2000; Guillemin et al. 2001, 2005b, 2007; Owe-Young et al. 2008), and is activated by immune-related molecules, such as lipopolysaccharides and inflammatory cytokines, particularly IFN-c ( Yoshida and Hayaishi 1978 ).”
BackgroundThe end of the road for the tryptophan depletion concept in pregnancy and infection
Badawy, A. A.-B., Namboodiri, A. M. A., & Moffett, J. R. (2016) · Clinical Science · doi:10.1042/cs20160153 · Cited by 92
Metadata
- Authors
- Yoshida, R., & Hayaishi, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1978-08
- Volume
- 75
- Issue
- 8
- Pages
- 3998-4000
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2020036812
- Cited by
- 181
- References
- 0
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.